Weight Loss Stack

14.9% of body weight gone in 68 weeks. That number, from the STEP 1 trial (PMID 33567185, n=1,961), turned semaglutide into the most prescribed weight loss drug in modern medicine. Semaglutide (CAS 910463-68-2) is a GLP-1 receptor agonist sold as Ozempic, Wegovy, Wegovy HD, and Rybelsus. The drug mimics incretin hormone GLP-1. It binds receptors in the pancreas, the gut, and satiety centers in the hypothalamus. Pancreatic binding increases insulin secretion. Gut binding slows gastric emptying. Brain binding turns down hunger signals. An albumin-binding fatty acid side chain extends the half-life to roughly 7 days, allowing once-weekly dosing. Real-world use spans three FDA indications. Obesity patients follow the Wegovy titration from 0.25 mg up to 2.4 mg weekly (or 7.2 mg with the high-dose label approved March 2026). Type 2 diabetics typically land between 0.5 and 2.0 mg weekly on the Ozempic label. Cardiovascular patients stay at 2.4 mg long-term after SELECT (PMID 37952131) confirmed a 20% reduction in major adverse cardiovascular events across 17,604 participants. Community experience tracks the clinical data closely. Over 350,000 combined members across r/Ozempic and r/semaglutide consistently report appetite suppression, steady 1 to 2 lbs per week weight loss, and reduced food noise within the first month. The honest caveat: two-thirds of the weight returns within a year of stopping (STEP 1 extension data). Lean mass loss of 25 to 40% without resistance training is well-documented. This is a long-term commitment, not a quick fix. In SURMOUNT-5 (PMID 40353578, n=751), semaglutide 2.4 mg produced 13.7% weight loss versus 20.2% for tirzepatide 15 mg at 72 weeks. Semaglutide holds the stronger cardiovascular outcomes dataset: the SELECT trial (PMID 37952131, n=17,604) confirmed a 20% reduction in major adverse cardiovascular events over 39.8 months.

2.8 kg of extra fat loss versus placebo over 12 weeks. That was the Phase IIa result for the AOD-9604 peptide (also called hGH fragment 177-191 or hGH frag, CAS 221231-10-3) in roughly 300 obese adults taking 1 mg orally per day (Obesity Research 2000, PMID 10950816). Then the larger Phase IIb trial with 536 subjects ran for 24 weeks, added strict diet and exercise controls, and missed its primary endpoint. Metabolic Pharmaceuticals terminated the program in 2007. The mechanism is specific. AOD-9604 activates beta-3 adrenergic receptors on adipocytes, triggering lipolysis while blocking lipogenesis. Unlike full-length growth hormone, it does not bind the GH receptor. Blood sugar stays flat. IGF-1 stays flat. Styer and colleagues confirmed this receptor selectivity in beta-3-AR knockout mice (Endocrinology 2001, PMID 11713213), where the lipolytic effect disappeared completely. Community use looks different from the clinical program. Most users inject 300 to 500 mcg subcutaneously each morning on an empty stomach. That dose range comes from converting the 1 mg oral clinical dose using an estimated 40% oral bioavailability from animal models. No published human SC pharmacokinetic study has validated this conversion. Across 50 to 150 Reddit threads in r/Peptides, the consensus is consistent: AOD-9604 is a mild add-on, not a primary fat loss tool. It performs best when stacked with CJC-1295 and Ipamorelin in a caloric deficit. Anyone expecting GLP-1-level results will be disappointed.